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Abstract
Cervical spine involvement may lead to severe complications in rheumatoid arthritis (RA). In the era of modern therapies, 
atlantoaxial subluxation (AAS) may be rare; however, it may still be detected in asymptomatic patients. The onset of myelopa-
thy can occur at any time. Altogether 49 female RA patients were included. Among them, 15 were methotrexate treated, 
biologic free, while 34 patients received biologics. The patients had no cervical pain or any neurological symptoms. We 
assessed the first (C1) and second (C2) cervical vertebrae by 3 T magnetic resonance imaging (MRI). In addition to AAS, 
we also determined odontoid erosion or periodontal soft tissue thickening. We associated our MRI findings with clinical, 
laboratory parameters, and hand radiography. We detected anterior AAS and soft tissue thickening in one-quarter, while 
odontoid erosions in eight (16%) of RA patients. There were no significant differences among the therapeutic subgroups. No 
posterior or vertical AAS was seen. Anterior AAS was associated with higher degree of inflammation, soft tissue thickening 
was seen at younger age, while odontoid erosions were associated with van der Heijde–Sharp scores of the hand. None of the 
patients had any lesions requiring surgery. The presence of cervical involvement in RA patients with 10–11 years of disease 
duration is still an important and frequent phenomenon. Higher disease activity and erosive disease are associated with 
atlantoaxial involvement. 3 T MRI is a sensitive method to assess AAS, as well as soft tissue lesions and odontoid erosions.
Keywords Rheumatoid arthritis · Atlantoaxial subluxation · Cervical spine involvement · Odontoid erosion
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory rheu-
matic disease often involving the small joints of the hands 
and feet, the wrists, elbows, ankles, and knees [1]. RA 
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may also involve the cervical spine in 20–70% of patients 
[1–4] and may start early during the disease course [5]. 
The atlantooccipital and atlantoaxial joints are the only 
vertebral segments without intervertebral disk. They com-
prise exclusively synovial joints. Therefore, these sections 
of the cervical spine are mostly affected by RA [6].
Chronic inflammation associated with RA may cause 
chronic synovitis, erosive pannus leading to odontoid ero-
sion, laxity of ligaments, spinal instability, and subluxa-
tion in the atlantoaxial joint (AAS) [2, 4]. AAS can be 
anterior, posterior or vertical. Anterior AAS is the most 
common form and results from the laxity of ligaments. 
Posterior and vertical AAS are less frequently observed. 
Posterior AAS is mainly due to erosion of the dens and it 
is associated with a higher risk of cord compression com-
pared to anterior AAS. Vertical AAS is the consequence of 
vertebral destruction and may even cause cranial settling 
with basal invagination [2–4, 7].
During the course of RA, the involvement of the cervi-
cal spine has no clinical symptoms for a long time due to 
the adaptability of neurological structures [5, 8]. Neuro-
logical signs may not be present up to 10 mm of AAS [8]. 
Suboccipital pain may be the first symptom of AAS [9]; 
however, it may be absent in more than half of patients 
with known instability [10]. Dizziness, tinnitus, and dys-
phagia may also occur [8, 10].
Functional cervical spine X-rays or MRI screening 
may detect asymptomatic abnormalities that may become 
symptomatic even after a sudden movement, trauma or 
retroposition of the head during anesthesia [2, 3, 6, 7, 
11]. Moreover, surgical anesthesia relaxes the defensive 
muscles further increasing the risk of cord compression. 
Therefore, assessment of cervical spine involvement in RA 
patients should be part of preoperative workup [6, 12].
Spinal cord involvement is the most serious complica-
tion. Myelopathy could result in severe pain, irreversible 
neurologic deficits, respiratory dysfunction, and conse-
quent death [6, 13]. Therefore, early diagnosis and proper 
treatment take priority. Surgical indications are therapy-
resistant pain and neurologic deficits [6, 13].
According to the current European League Against 
Rheumatism (EULAR) recommendations, cervical spine 
involvement should primarily be detected by neutral posi-
tion and functional X-rays of the cervical spine [11]. MRI 
scanning is more sensitive than conventional radiographs, 
showing early structural damage of the joints, as well as 
soft tissue involvement including periodontal synovitis, 
fibrous pannus, and odontoid erosions. MRI provides not 
only lateral, but also sagittal and coronal views and give 
explicit information of the soft tissue, as well as lesions 
of the neuraxis and epidural tissues. MRI should be per-
formed if the patient has neurologic deficit or if there is 
indication of surgery [6, 11, 14].
With the introduction of effective treatments including 
targeted therapies and the treat-to-target strategy, cervical 
spine involvement in RA has become rare [6, 15]. Early ini-
tiation of therapy may prevent further cartilage destruction 
and ligamentous laxity [6]. However, it still remains an issue 
to select patients with an increased risk of cervical spine 
involvement to initiate therapeutic intervention before neu-
rologic deterioration occurs [6, 15]. We found only very few 
reports on the association of biological therapy and cervical 
spine pathology in RA [15–17]. Thus, in the present cross-
sectional study we wished to assess cervical spine involve-
ment in Hungarian RA patients undergoing biologic versus 
methotrexate (MTX) therapy. In addition, as more powerful 
MRI instruments have recently become available, we wished 
to test the value of 3 T MRI imaging in the detection of cer-
vical spine abnormalities.
Patients and methods
Forty-nine RA patients undergoing regular follow-ups at the 
Borsod County Teaching Hospital, Miskolc were recruited 
for the study. Patients with RA were in stable remission or 
with low disease activity. None of them had any cervical 
pain or neurological symptoms.
The major characteristics of these 49 patients are shown 
in Table 1. All patients were females, their median age was 
60 (range 43–78) years. Their median disease duration was 
9 (range 0.5–36) years. Altogether 71% were IgM rheu-
matoid factor (RF) positive, and 67% were ACPA (anti-
CCP2) positive. Among these patients, 15 were biologic 
free. They had been receiving MTX for a median 6 (range 
0.5–15) years in an average dose of 15 (range 7.5–20) mg/
week. Altogether 34 patients had been receiving biologics 
[17 infliximab (IFX) as first-line biologic treatment and 17 
tocilizumab (TCZ) as second-line biologic treatment after 
a failure of anti-TNF therapy], in combination with MTX. 
The median duration of biologic therapy was 5 (1–10) years, 
the median duration of MTX in the biologic-treated group 
was 5.5 (0.5–12) years in an average dose of 15 (7.5–25) 
mg/week. All patients underwent regular follow-ups every 
3 months in the last 3 years.
Ethical approval (1046-63/2015) was obtained from the 
University of Miskolc Regional/Institutional Review Board. 
All patients signed informed consent forms. The study was 
performed according to the Declaration of Helsinki.
The study design is included in Fig. 1.
Cervical spine MRI investigations
All 49 RA patients underwent cervical MRI imaging in neu-
tral position. We assessed the atlas and the axis to explore 
the inflammatory cervical spine involvement of RA patients. 
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For this purpose, a Siemens Magnetom Verio 3 T (3 T) MRI 
instrument (Siemens, Munich, Germany) was used. All 
MRI scans were performed by a single radiologist (L. K.) 
and also read by a neurosurgeon/neuroradiologist (C. O.). 
The presence or absence of AAS, odontoid erosion, and peri-
odontal soft tissue thickening were noted. AAS is defined by 
an increase in the atlantodental interval (ADI), the distance 
between the anterior surface of the dens and the posterior 
surface of C1, of > 3 mm. ADI > 3.5 mm means instability 
and ADI > 10 mm is an indication for surgery. None of the 
patients underwent plain radiography as we intended to detect 
early lesions. Therefore, all patients directly went for MRI.
Laboratory assessments
Serum IgM RF and high sensitivity CRP (hsCRP) were 
assessed by quantitative nephelometry (Cobas Mira Plus, 
Roche), using RF and CRP reagents, respectively (both 
Dialab, Vienna, Austria). RF levels > 50 IU/ml indicated 
seropositivity and hsCRP levels > 5 mg/l were considered 
elevated. Anti-CCP autoantibodies were detected in serum 
samples using the second generation Immunoscan-RA CCP2 
ELISA test (Euro Diagnostica, Arnhem, The Netherlands). 
The assay was performed according to the instructions of 
the manufacturer. A concentration > 25 IU/ml indicated 
seropositivity.
We also calculated the mean ESR (mESR), CRP (mCRP) 
and DAS28 (mDAS28) values based on three monthly 
assessments within the past 3 years (up to 12 assessments) 
(Table 1). We applied the EULAR DAS28 remission and 
low disease activity criteria: DAS28 remission: < 2.6, low 
disease activity < 3.2.
Hand X‑ray analysis
All RA patients underwent hand X-rays at the time of the 
cervical spine MRI study. Radiographs of the hand are used 
to determine the degree of disease progression. Erosions 
were scored according to the modified van der Heijde–Sharp 
method [18]. Each joint was graded on a score of 0 (normal) 
to 5 (maximal destruction).
Each radiograph was scaled by the same radiologist (L. 
K.) and then by a single rheumatologist (Z. K.), and the 
results were averaged.
Statistical analysis
The statistical analysis was processed using the IBM SPSS 
25 software. Data are expressed as median and range. The 
Table 1  General characteristics and disease activity markers of RA patients
Significant differences are indicated in bold
ACPA, anti-citrullinated protein antibody; biol., biologic; CRP, C-reactive protein; DAS28, 28-joint disease activity score; ESR, erythrocyte sed-
imentation rate; IFX, infliximab; mCRP, mean CRP; mDAS28, mean DAS28; mESR, mean ESR; MTX, methotrexate; RA, rheumatoid arthritis; 
RF, rheumatoid factor; TCZ, tocilizumab; vdHSS, modified van der Heijde–Sharp score
RA (total) RA (MTX) RA (biol.) p (MTX vs 
biol.)
RA (IFX) RA (TCZ) p (IFX vs TCZ)
n 49 15 34 17 17
Age (years) 60 (43–78) 61 (47–77) 59 (43–78) 0.415 60 (45–78) 58 (43–76) 0.436
Disease duration 
(years)
9 (0.5–36) 8 (0.5–30) 9 (4–36) 0.948 9 (5–36) 10 (4–22) 0.904
RF positivity, 
n (%)
34 (71) 11 (73) 23 (70) 0.750 10 (59) 13 (76) 0.465
ACPA positiv-
ity, n (%)
25 (67) 6 (67) 19 (68) 0.652 8 (53) 11 (76) 0.665
MTX duration 
(years)
6 (0.5–15) 6 (0.5–15) 5.5 (0.5–12) 0.802 7 (3–11) 5 (0.5–12) 0.291
MTX dose (mg/
week)
15 (7.5–25) 15 (7.5–20) 15 (7.5–25) 0.322 10 (7.5–20) 20 (7.5–25) 0.042
Biologic dura-
tion (years)
– – 5 (1–10) – 6 (3–8) 5 (1–10) 0.061
mDAS28 2.62 (0.75–4.34) 3.23 (1.86–4.34) 2.59 (0.75–3.69) 0.036 2.78 (1.8–3.69) 2.2 (0.75–3.29) < 0.001
mESR (mm/h) 14.47 (2.62–
57.33)
18.56 (4.33–
57.33)
13.56 (2.62–
50.86)
0.221 22.38 (9.62–
50.86)
9.56 (2.62–24) < 0.001
mCRP (mg/l) 5 (0.16–26.3) 7.71 (1.71–26.3) 4.61 (0.16–
24.37)
0.050 5.08 (0.46–
24.37)
4.6 (0.16–
24.37)
0.399
vdHSS (hand) 17 (0–146) 16 (2–86) 18 (0–146) 0.914 15 (0–146) 26 (3–70) 0.040
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distribution of continuous variables was examined by Kol-
mogorov–Smirnov test. Differences were evaluated by inde-
pendent two-tailed t test or Mann–Whitney test as appro-
priate. Nominal variables were compared between groups 
using the Chi-squared or Fisher’s exact test, as appropriate. 
p values < 0.05 were considered significant.
We perfomed sample size power calculations. This indi-
cated with respect to the three most important findings 
(Table 3, see later), the power percentages were 82%, 93%, 
and 83%. Usually, power > 80% is acceptable, so our study 
was well powered.
Results
Comparative description of RA patient subsets
With respect to clinical and disease activity markers, the 
total RA cohort, the MTX- and biologic-treated RA subsets 
did not differ from each other in most respects (Table 1). 
However, MTX-treated patients had significantly higher 
mDAS28 [3.23 (1.86–4.34) vs 2.59 (0.75–3.69); p = 0.036] 
than biologic-treated patients (Table 1). Moreover, TCZ-
treated patients had significantly lower mDAS28 [2.2 
(0.75–3.29) vs 2.78 (1.8–3.69); p < 0.001], mESR [9.56 
(2.62–24) mm/h vs 22.38 (9.62–50.86) mm/h; p < 0.001] and 
higher modified van der Heijde–Sharp scores (vdHSS) [26 
(3–70) vs 15 (0–146); p = 0.040), compared to IFX-treated 
individuals (Table 1).
Cervical spine MRI investigations
Anterior AAS developed in 26.5% of all RA patients, 20.0% 
of the MTX- and 29.4% of the biologic-treated subset. 
Within the biologic-treated subset, 23.5% of IFX- and 35.3% 
of TCZ-treated patients had anterior AAS (Table 2). Soft tis-
sue thickening was observed in 24.5%, 33.3%, 20.6%, 35.3%, 
and 5.8% of all MTX-, any biologic-, IFX-, and TCZ-treated 
RA patients, respectively (Table 2). Finally, odontoid ero-
sion was seen in 16.3% of all RA patients, 20.0% in MTX- 
and 14.7% of any biologic-treated, as well as in 11.8% of 
IFX- and 17.7% of TCZ-treated patients (Fig. 2; Table 2). 
There were no significant differences between MTX- and 
biologic-treated patients with respect to any MRI finding. 
Moreover, within the biologic-treated subset, there were 
no differences between the IFX- and TCZ-treated subsets 
(Table 2). No posterior or vertical AAS was detected in any 
patient.
Associations of cervical spine MRI pathologies 
with clinical, laboratory and hand X‑ray parameters
Patients with anterior AAS had significantly higher mCRP 
compared to those without AAS [10.17 (2.16–21.8) vs 4.6 
(0.16–26.32) mg/l; p = 0.019) (Table 3). Patients with AAS 
Fig. 1  Study flowchart
Table 2  Cervical spine MRI pathologies in the total RA cohort and in RA subsets
AAS, atlantoaxial subluxation; biol., biologic; IFX, infliximab; MRI, magnetic resonance imaging; MTX, methotrexate; RA, rheumatoid arthri-
tis; TCZ, tocilizumab
RA (total) RA (MTX) RA (biol.) p (MTX vs biol.) RA (IFX) RA (TCZ) p (IFX vs TCZ)
n 49 15 34 17 17
Anterior AAS, n (%) 13 (26.5) 3 (20.0) 10 (29.4) 0.727 4 (23.5) 6 (35.3) 0.708
Soft tissue thickening, n (%) 12 (24.5) 5 (33.3) 7 (20.6) 0.473 6 (35.3) 1 (5.8) 0.085
Odontoid erosion, n (%) 8 (16.3) 3 (20.0) 5 (14.7) 0.687 2 (11.8) 3 (17.7) 1.000
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also had a tendency of higher mDAS28 and MTX dose, but 
these differences were not statistically significant (Table 3) 
(power: 82%). Patients with soft tissue thickening on MRI 
were significantly younger compared to those without 
this feature [54.5 (45–63) vs 61 (43–78) years; p = 0.013] 
(Table 3) (power: 93%). There was also a non-significant 
tendency of higher mDAS28 and mESR in patients with 
soft tissue thickening (Table 3). Finally, patients with odon-
toid erosion had significantly higher vdHSS compared to 
those without odontoid erosion [38 (21–86) vs 16 (0–146); 
p = 0.007) (Table 3) (power: 83%). With respect to other 
parameters, such as disease duration, seropositivity, MTX 
dose and duration, biologic treatment and its duration, TCZ 
versus IFX treatment, there were no differences between the 
three patient subsets (Table 3).
Fig. 2  MRI assessment of a patient with rheumatoid arthritis. Arrow 
points to odontoid erosion and destruction of the dens
Table 3  Associations of cervical spine MRI pathologies with other parameters in RA patients
Significant differences are indicated in bold
AAS, atlantoaxial subluxation; ACPA, anti-citrullinated protein antibody; CRP, C-reactive protein; DAS28, 28-joint disease activity score; ESR, 
erythrocyte sedimentation rate; IFX, infliximab; mCRP, mean CRP; mDAS28, mean DAS28; mESR, mean ESR; MRI, magnetic resonance 
imaging; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; TCZ, tocilizumab; vdHSS, modified van der Heijde–Sharp score
Patients with 
AAS
Patients with-
out AAS
P Patients with 
soft tissue 
thickening
Patients with-
out soft tissue 
thickening
p Patients with 
odontoid ero-
sion
Patients with-
out odontoid 
erosion
p
n 13 36 10 39 8 41
Age (years) 60 (45–76) 60 (43–78) 0.642 54.5 (45–63) 61 (43–78) 0.013 57.5 (50–61) 61 (43–78) 0.067
Disease dura-
tion (years)
8 (4–22) 9.5 (0.5–36) 0.370 8 (2–20) 10 (0.5–36) 0.412 8.5 (4–12) 8 (0.5–36) 0.532
mESR (mm/h) 17.67 (7.8–
39.86)
14 (2.62–57.33) 0.668 23.31 (4.33–
50.86)
13.33 (2.62–
57.33)
0.243 12.66 
(7.8–39.86)
14.57 (2.62–
57.33)
0.596
mCRP (mg/l) 10.17 (2.16–
21.8)
4.6 (0.16–
26.32)
0.019 3.69 (0.46–
21.80)
5.08 (0.16–
26.32)
0.687 4.77 (0.46–
21.80)
5.12 (0.16–
26.32)
1.000
mDAS28 2.92 (1.86–
3.65)
2.56 (0.75–
4.34)
0.171 3.38 (1.94–
3.69)
2.58 (0.75–
4.34)
0.105 3.08 (1.86–3.5) 2.59 (0.75–
4.34)
0.559
RF+ and/or 
ACPA+, n 
(%)
10 (77) 24 (67) 0.727 7 (70) 27 (69) 1.000 6 (75) 28 (68) 1.000
vdHSS (hand) 21 (3–64) 16 (0–146) 0.587 13 (2–86) 18 (0–146) 0.599 38 (21–86) 16 (0–146) 0.007
MTX therapy 
duration 
(years)
6 (0.5–11) 6 (0.5–15) 0.733 6 (0.5–11) 6 (0.5–15) 0.836 6 (0.5–11) 6 (0.5–15) 0.681
MTX dose (mg/
week)
20 (7.5–25) 15 (7.5–20) 0.115 15 (7.5–20) 15 (7.5–25) 0.599 17.5 (7.5–25) 15 (7.5–20) 0.256
Biologic-
treated, n (%)
10 (77) 24 (67) 0.727 6 (60) 28 (72) 0.470 5 (63) 29 (71) 0.687
Biologic 
therapy dura-
tion (years)
5 (1–7) 5 (2–10) 0.867 6.5 (1–8) 5 (2–10) 0.388 6 (1–7) 5 (2–10) 0.925
IFX, n 4 13 0.708 5 12 0.174 2 15 1.000
TCZ, n 6 11 1 16 3 14
 Rheumatology International
1 3
Discussion
Cervical spine involvement, a serious complication of RA, 
can be observed even in recent times, in the era of mod-
ern therapies. AAS, soft tissue thickening, or odontoid 
erosion may be identified even in asymptomatic patients. 
Isolated, mostly anterior AAS may develop early in the 
disease course and it can later be complicated with soft tis-
sue involvement and odontoid erosions. Myelopathy may 
occur at any time initially leading to headache and neck 
pain, followed by more advanced neurological symptoms 
[8–11, 14]. As 3 T MRI instruments have only recently 
become available, we wished to try this technique to assess 
cervical spine pathology in RA. Moreover, there have 
been only very few reports with respect to cervical spine 
involvement in biologic-treated RA patients [15–17]. Our 
cohort included 49 RA patients with no cervical spine and 
neurological symptoms.
In RA, the most common cervical spine involvement 
is anterior AAS. We found this lesion in about quarter 
of our RA patients. Carotti et al. [14] described cervical 
involvement in 24% of early RA patients (disease dura-
tion < 12 months). In our cohort, anterior AAS was asso-
ciated with higher mCRP and there was also a tendency 
of association with higher mDAS28 and MTX dose. In 
other studies, seropositivity, early onset of RA, high dis-
ease activity scores, erosive disease at baseline, and use 
of corticosteroids were predictors of AAS [7, 14]. Hand 
X-ray findings may also potentially predict AAS in RA 
[19]. In our hands, AAS was not associated with vdHSS. 
Importantly, the progressive damage of peripheral joints 
with indication of prosthetic implantation was also asso-
ciated with cervical spine involvement. In RA, patients 
scheduled for hip or knee replacement surgery, 44–65% 
demonstrated AAS on pre-surgical radiographs [10].
MRI may be very useful when assessing cervical spine 
pathologies in RA as this technique, in comparison to con-
ventional radiography, may also detect soft tissue thicken-
ing and odontoid erosions. We assessed our patients, in 
addition to AAS, for signs of synovitis and fibrotic pannus 
in the joints of C1 and C2 vertebrae, as well as for ero-
sive lesions of the dens. Again, approximately quarter of 
our patients had soft tissue thickening and 16% had dens 
erosions. Interestingly, soft tissue thickening occurred at 
younger age, while odontoid erosions were associated with 
higher vdHSS indicating more pronounced peripheral joint 
destruction. As discussed above, in other studies, struc-
tural damage of small joints of the hand was rather associ-
ated with AAS [19].
As there have been few reports on the association 
of biologic therapy with cervical spine involvement 
in RA [15–17], we also tried to compare MTX- versus 
biologic-treated, as well as, within the biologic-treated 
subset, also IFX- versus TCZ-treated RA patient subsets. 
In our cross-sectional study, MTX- and biologic-treated 
patients had similar clinical features. Only mDAS28 was 
higher in the MTX-treated group. On the other hand, 
TCZ-treated patients had lower mDAS28 and mESR and 
somewhat lower mCRP compared to IFX-treated patients 
indicating that IFX and TCZ may have different effects 
on inflammatory activity. However, TCZ-treated patients 
had higher vdHSS suggesting that this subset may reflect 
a more severe group of patients. Despite these clinical 
and radiological differences between the RA subsets, no 
significant differences were found between any two patient 
subset with respect to AAS, soft tissue thickening or odon-
toid erosions. In 2019, Sandstrom et al. [15] published 
very recent data from the NEORACo early arthritis cohort. 
In this study, 99 treatment-naïve RA patients received con-
ventional DMARD and corticosteroid and then they were 
randomized to receive IFX or placebo. After 10 years, 
4.7% of the analyzed patients had cervical spine involve-
ment. There were only two cases with AAS, both treated 
with IFX [15]. Thus, in early RA patients managed accord-
ing to the treat-to-target strategy, AAS is relatively rare 
compared to our patients with 10–11 years of disease dura-
tion. Salli et al. [16] reported successful IFX treatment 
of periodontoid pannus in one RA patient. We have not 
found any other reports on the possible effects of biolog-
ics on cervical spine pathologies in RA. Kanayama et al. 
[17], who conducted a prospective study on 47 RA patients 
and received IFX for at least 1 year. IFX was able to sup-
press the progression of cervical lesions in 83% of patients 
showing good clinical response to IFX [17]. We did not 
find any reports with respect to TCZ treatment.
Our study has strengths and limitations. The major 
strength is its novelty studying cervical spine involvement 
in RA in the era of modern therapies, as well as the use of 
new 3 T MRI technology. Possible limitations include the 
relatively small number of patients, especially in the thera-
peutic subsets and the cross-sectional nature of our study. 
In addition, our cohort includes patients with longer disease 
duration; therefore, cervical spine pathologies are relatively 
more common than in early arthritis cohorts.
In conclusion, 3 T MRI may assess soft tissue involve-
ment and odontoid erosions in addition to AAS. Despite of 
biologic therapy, 15–30% of RA patients still have preclini-
cal cervical spine abnormalities that may be associated with 
higher degree of systemic inflammation and structural hand 
joint changes. MRI is a sensitive method to assess cervical 
spine involvement in RA patients with otherwise no neuro-
logical symptoms.
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